COVID-19-associated heart failure: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Line 18: Line 18:
==Classification==
==Classification==


*[[Heart Failure]] ([[(HF)]] in [[COVID-19]] may be classified similarly to [[heart failure]] from other causes.  
*Heart Failure in COVID-19 may be classified similarly to heart failure from other causes.  
* In general, [[heart failure]] can be classified based on:
* In general, HF can be classified based on:
**'''The pathophysiology of heart failure''':  
**The pathophysiology of heart failure:  
***[[systolic HF]] vs [[diastolic HF]]
***systolic vs diastolic  
***[[left-sided HF]] vs [[right-sided HF]]
***left-sided vs right-sided
**'''The duration of symptoms''':
**The duration of symptoms:
***acute HF [[(AHF)]] vs chronic HF [[(CHF)]]
***acute vs chronic
**'''The underlying physiology based on [[left ventricular ejection fraction (LVEF)]]:'''
**The underlying physiology based on left ventricular ejection fraction (LVEF):
***[[Heart failure with reduced ejection fraction]] [[(HFrEF)]] vs [[heart failure with mid-range ejection fraction]] [[(HFmrEF)]] and [[heart failure with preserved ejection fraction]] [[(HFpEF)]]    
***Heart failure with reduced ejection fraction (HFrEF) vs heart failure with mid-range ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF),    
**'''The severity of [[heart failure]]''' (i.e., the [[New York Heart Association Class]] I-IV)
**The severity of heart failure (i.e., the New York Heart Association Class I-IV)
**'''The stage of congestive heart failure''' (i.e., [[AHA Class A, B, C, D]])
**The stage of congestive heart failure (i.e., AHA Class A, B, C, D)


*[[Acute heart failure]] has two forms:
*Acute heart failure has two forms:
**Newly-arisen (“de novo”) acute heart failure  
**Newly-arisen (“de novo”) acute heart failure  
**Acutely decompensated chronic heart failure (ADCHF)
**Acutely decompensated chronic heart failure (ADCHF)
Line 36: Line 36:
==Pathophysiology==
==Pathophysiology==


*Presumed pathophysiologic mechanisms for the development of new or decompensated heart failure in patients with [[COVID-19]] include:<ref name="pmid32219357">{{Cite pmid|32219357}}</ref> <ref name="pmid32360242">{{Cite pmid|32360242}}</ref> <ref name="pmid32186331">{{Cite pmid|32186331}}</ref> <ref name="pmid30625066">{{Cite pmid|30625066}}</ref> <ref name="pmid32140732">{{Cite pmid|32140732}}</ref>
*Presumed pathophysiologic mechanisms for the development of new or decompensated heart failure in patients with COVID-19 include:<ref name="pmid32219357">{{cite journal| author=Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D | display-authors=etal| title=Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). | journal=JAMA Cardiol | year= 2020 | volume=  | issue=  | pages=  | pmid=32219357 | doi=10.1001/jamacardio.2020.1096 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32219357 }} </ref> <ref name="pmid32360242">{{Cite pmid|32360242}}</ref> <ref name="pmid32186331">{{Cite pmid|32186331}}</ref> <ref name="pmid30625066">{{Cite pmid|30625066}}</ref> <ref name="pmid32140732">{{Cite pmid|32140732}}</ref>
      
      
**Acute exacerbation of [[chronic heart failure]] caused by precipitating factors
**Acute exacerbation of [[chronic heart failure]] caused by precipitating factors
Line 43: Line 43:
**Impaired myocardial relaxation resulting in [[diastolic dysfunction]] [i.e., [[Heart failure with preserved ejection fraction (HFpEF)]] ]
**Impaired myocardial relaxation resulting in [[diastolic dysfunction]] [i.e., [[Heart failure with preserved ejection fraction (HFpEF)]] ]
**Right-sided heart failure, secondary to [[pulmonary hypertension]] caused by hypoxia and [[acute respiratory distress syndrome]] (ARDS)
**Right-sided heart failure, secondary to [[pulmonary hypertension]] caused by hypoxia and [[acute respiratory distress syndrome]] (ARDS)


==Causes==
==Causes==


*[[Acute myocardial injury]]
*Acute myocardial injury
*[[Acute coronary syndromes]]
*Acute coronary syndromes
*[[Myocarditis]]
*Myocarditis
*[[Hypertensive crisis]]
*Hypertensive crisis
*[[Arrhythmias]]: Tachycardia or severe bradycardia
*Arrhythmias: Tachycardia or severe bradycardia
*[[Stress-induced cardiomyopathy]]
*Stress-induced cardiomyopathy
*Circulatory failure:
*Circulatory failure:
**[[Acute pulmonary embolism]]
**Acute pulmonary embolism
**[[Pericardial tamponade]]
**Pericardial tamponade
*Iatrogenic
*Iatrogenic


Line 61: Line 60:
==Differentiating ((COVID-19 associated heart failure)) from other Diseases==
==Differentiating ((COVID-19 associated heart failure)) from other Diseases==


In patients with [[COVID-19]] infection, [[acute heart failure]] should be differentiated from other diseases presenting with [[dyspnea]] and/or [[tachypnea]].
In patients with COVID-19 infection, acute heart failure should be differentiated from other diseases presenting with dyspnea and/or tachypnea.
The differentials include the following:
The differentials include the following:
*[[Pneumonia]]
*Pneumonia
*[[ARDS]]
*ARDS
*[[Myocarditis]]/[[pericarditis]]
*Myocarditis/pericarditis
*[[Acute pulmonary embolism]]
*Acute pulmonary embolism




==Epidemiology and Demographics==
==Epidemiology and Demographics==
*Data on incidence on acute heart failure in COVID-19 patients is limited.
*In one study, acute heart failure was seen in 4.1% of patients with acute cardiac injury.  
*In one study, [[acute heart failure]] was seen in 4.1% of patients with [[acute cardiac injury]].  
*In a retrospective study on study 191 COVID-19 patients in Wuhan, China, the incidence of heart failure was 23% (52% in non-survivors vs 12% in survivors).
*In a retrospective study on 191 [[COVID-19]] patients in Wuhan, China, the incidence of heart failure was 23% (52% in non-survivors vs 12% in survivors).


==Risk Factors==
==Risk Factors==
Line 83: Line 81:


==Natural History, Complications, and Prognosis==
==Natural History, Complications, and Prognosis==
*[[COVID-19]] patients with [[chronic heart failure]] are more likely to develop severe forms of the disease.
*COVID-19 patients with chronic heart failure are more likely to develop severe forms of the disease.
*[[COVID-19]] patients who develop [[acute heart failure]] (either de novo AHF or ADHF) have worse outcomes.
*COVID-19 patients who develop acute heart failure (either de novo AHF or ADHF) have worse outcomes.
*[[Acute heart failure]] in [[COVID-19]] may progress to [[cardiogenic shock]].  
*Acute heart failure in COVID-19 may progress to cardiogenic shock.  
    
    
==Diagnosis==
==Diagnosis==
Line 92: Line 90:
===History and Symptoms===
===History and Symptoms===


*The most common symptoms of [[acute heart failure]] in [[COVID-19]] patients are:
*The most common symptoms of acute heart failure in COVID-19 patients are:
**New or worsening [[dyspnea]]: may overlap with dyspnea caused by concomitant respiratory involvement and [[ARDS]] due to [[COVID-19]]
**New or worsening dyspnea: may overlap with dyspnea caused by concomitant respiratory involvement and ARDS due to COVID-19
**[[Peripheral edema]]
**Peripheral edema
**Confusion and altered mentation
**Confusion and altered mentation
**[[Orthopnea]]
**Orthopnea  
**[[Palpitations]]
**Palpitations  
*Less common symptoms include:
**Paroxysmal nocturnal dyspnea  
**[[Paroxysmal nocturnal dyspnea]]
**Cool extremities  
**Cool extremities  
**[[Cyanosis ]]
**Cyanosis  
**[[Dizziness]]
**Dizziness
**[[Syncope]]
**Syncope
**Fatigue
**Fatigue
**[[Hemoptysis]]
**Hemoptysis


===Physical Examination===
===Physical Examination===


*Physical examination of patients with [[acute heart failure]] is usually remarkable for:  
*Physical examination of patients with acute heart failure is usually remarkable for:  
**[[Crackles]] on auscultation
**Crackles on auscultation
**[[Distended jugular veins]]
**Distended jugular veins
**Lower extremity edema
**Lower extremity edema


Line 117: Line 114:


*Cardiac Troponins:
*Cardiac Troponins:
**Elevated [[cardiac troponin]] levels suggest the presence of myocardial cell injury or death.
**Elevated cardiac [[troponin]] levels suggest the presence of myocardial cell injury or death.
**Cardiac troponin levels may increase in patients with chronic or acute decompensated heart failure.<ref name="pmid20863950">{{Cite pmid|20863950}}</ref>
**Cardiac troponin levels may increase in patients with chronic or acute decompensated HF.<ref name="pmid20863950">{{Cite pmid|20863950}}</ref>


*Natriuretic Peptides:
*Natriuretic Peptides:
**[[Natriuretic peptides]] (BNP/NT-proBNP) are released from the heart in response to increased [[myocardial stress]] and are quantitative markers of increased [[intracardiac filling pressure]].<ref name="pmid28062628">{{Cite pmid|28062628}}</ref>
**[[Natriuretic peptides]] (BNP/NT-proBNP) are released from the heart in response to increased myocardial stress and are quantitative markers of increased intracardiac filling pressure.<ref name="pmid28062628">{{Cite pmid|28062628}}</ref>
**Elevated [[BNP]] and [[NT-proBNP]] are of both diagnostic and prognostic significance in patients with [[heart failure]].
**Elevated [[BNP]] and [[NT-proBNP]] are of both diagnostic and prognostic significance in patients with heart failure.
**Increased [[BNP]] or [[NT-proBNP]] levels have been demonstrated in COVID-19 patients.
**Increased BNP or NT-proBNP levels have been demonstrated in COVID-19 patients.
**Increased [[NT-proBNP]] level was associated with worse clinical outcomes in patients with severe COVID-19.<ref name="pmid32293449">{{Cite pmid|32293449}}</ref> <ref name="pmid32232979">{{Cite pmid|32232979}}</ref>
**Increased NT-proBNP level was associated with worse clinical outcomes in patients with severe COVID-19.<ref name="pmid32293449">{{Cite pmid|32293449}}</ref> <ref name="pmid32232979">{{Cite pmid|32232979}}</ref>
**However, increased [[natriuretic peptide]] levels are frequently seen among patients with severe inflammatory or respiratory diseases.<ref name="pmid18298480">{{Cite pmid|18298480}}</ref> <ref name="pmid16442916">{{Cite pmid|16442916}}</ref> <ref name="pmid28322314">{{Cite pmid|28322314}}</ref> <ref name="pmid23837838">{{Cite pmid|23837838}}</ref> <ref name="pmid21478812">{{Cite pmid|21478812}}</ref>
**However, increased natriuretic peptide levels are frequently seen among patients with severe inflammatory or respiratory diseases.<ref name="pmid18298480">{{Cite pmid|18298480}}</ref> <ref name="pmid16442916">{{Cite pmid|16442916}}</ref> <ref name="pmid28322314">{{Cite pmid|28322314}}</ref> <ref name="pmid23837838">{{Cite pmid|23837838}}</ref> <ref name="pmid21478812">{{Cite pmid|21478812}}</ref>
**Therefore, routine measurement of [[BNP]]/[[NT-proBNP]] has not been recommended in [[COVID-19 patients]], unless there is a high suspicion of [[heart failure]] based on clinical grounds.
**Therefore, routine measurement of BNP/NT-proBNP has not been recommended in COVID-19 patients, unless there is a high suspicion of HF based on clinical grounds.


===Electrocardiogram===
===Electrocardiogram===


*There is no specific electrocardiographic finding for [[acute heart failure]] in [[COVID-19 patients]].  
*There is no specific electrocardiographic finding for [[acute heart failure]] in COVID-19 patients.  
*The ECG may help in identifying preexisting cardiac abnormalities and precipitating factors, such as [[ischemia]], [[myocarditis]], and [[arrhythmias]].  
*The ECG may help in identifying preexisting cardiac abnormalities and precipitating factors, such as [[ischemia]], [[myocarditis]], and [[arrhythmias]].  
*These ECG findings may include:
*These ECG findings may include:
Line 142: Line 139:
===X-ray===
===X-ray===


*A [[Chest x-ray]] may be helpful in the diagnosis of [[heart failure]]. Findings on [[chest X-ray]] suggestive of [[heart failure]] include:
*An x-ray may be helpful in the diagnosis of [[heart failure]]. Findings on an x-ray suggestive of heart failure include:
**[[Cardiomegaly]]  
**[[Cardiomegaly]]  
**[[Pulmonary congestion]]
**Pulmonary congestion
**Increased pulmonary vascular markings.
**Increased pulmonary vascular markings.


*However, signs of [[pulmonary edema]] may be obscured by underlying respiratory involvement and [[ARDS]] due to [[COVID-19]].
*However, signs of [[pulmonary edema]] may be obscured by underlying respiratory involvement and ARDS due to COVID-19.


===Echocardiography or Ultrasound===
===Echocardiography or Ultrasound===


*A complete standard [[transthoracicechocardiography]] [[(TTE)]] has not been recommended in [[COVID-19]] patients considering the limited [[personal protective equipment (PPE)]] and the risk of exposure of additional health care personnel.<ref name="pmid32391912">{{Cite pmid|32391912}}</ref>
*A complete standard [[transthoracicechocardiography]] (TTE) has not been recommended in COVID-19 patients considering the limited personal protective equipment (PPE) and the risk of exposure of additional health care personnel.<ref name="pmid32391912">{{Cite pmid|32391912}}</ref>
*To deal with limited resources (both personal protective equipment and personnel) and reducing the exposure time of personnel, a focused TTE to find gross abnormalities in cardiac structure/function seems satisfactory.  
*To deal with limited resources (both personal protective equipment and personnel) and reducing the exposure time of personnel, a focused TTE to find gross abnormalities in cardiac structure/function seems satisfactory.  
*In addition, bedside options, which may be performed by the trained personnel who might already be in the room with these patients, might also be considered. These include:
*In addition, bedside options, which may be performed by the trained personnel who might already be in the room with these patients, might also be considered. These include:
**[[Cardiac point-of-care ultrasound]] [[(POCUS)]]
**[[Cardiac point-of-care ultrasound]] (POCUS)  
**[[Focused cardiac ultrasound study]] [[(FoCUS)]]
**Focused cardiac ultrasound study (FoCUS)  
**Critical care echocardiography  
**Critical care echocardiography  


*Cardiac ultrasound can help in assessing the following parameters:
*Cardiac ultrasound can help in assessing the following parameters:
**[[Left ventricular systolic function]] [[(left ventricular ejection fraction, LVEF)]] to distinguish [[systolic dysfunction]] with a [[reduced ejection fraction]] (LVEF<40%) from [[diastolic dysfunction]] with a preserved ejection fraction (LVEF>40%)
**Left ventricular systolic function (ejection fraction) to distinguish systolic dysfunction with a reduced ejection fraction (<40%) from diastolic dysfunction with a preserved ejection fraction.
**Left ventricular [[diastolic function]]
**Left ventricular diastolic function
**Left ventricular structural abnormalities, including [[left ventricular size]] and [[left ventricular wall thickness]]
**Left ventricular structural abnormalities, including LV size and LV wall thickness
**Left atrial size
**Left atrial size
**Right ventricular size and function
**Right ventricular size and function
**Detection and quantification of [[valvular abnormalities]]
**Detection and quantification of valvular abnormalities
**Measurement of [[systolic pulmonary artery pressure]]
**Measurement of systolic pulmonary artery pressure
**Detection and quantification of [[pericardial effusion]]
**Detection and quantification of pericardial effusion
**Detection of [[regional wall motion abnormalities]]/reduced [[strain]] that would suggest underlying [[ischemia]].
**Detection of [[regional wall motion abnormalities]]/reduced [[strain]] that would suggest underlying [[ischemia]].


Line 180: Line 177:
===Medical Therapy===
===Medical Therapy===


*[[Acute heart failure]] in the setting of [[COVID-19]] is generally treated similarly to [[acute heart failure]] in other settings. These may include:  
*Acute heart failure in the setting of COVID-19 is generally treated similarly to acute heart failure in other settings. These may include:  
**[[Fluid restriction]]
**Fluid restriction
**[[Diuretic]] therapy
**Diuretic therapy
**[[Vasopressors]] and/or [[inotropes]]  
**[[Vasopressors]] and/or [[inotropes]]  
**[[Ventricular assisted devices]] and [[extracorporeal membrane oxygenation (ECMO)]]  
**[[Ventricular assisted devices]] and [[extracorporeal membrane oxygenation (ECMO)]]  
*[[Beta-blockers]] should not be initiated during the acute stage due to their [[negative inotropic effects]].<ref name="pmid24251454">{{Cite pmid|24251454}}</ref>
*[[Beta-blockers]] should not be initiated during the acute stage due to their negative inotropic effects.<ref name="pmid24251454">{{Cite pmid|24251454}}</ref>
*[[Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)]] should be used with caution in patients with [[acute heart failure]] due to their effect on fluid and sodium retention.<ref name="pmid12656651">{{Cite pmid|12656651}}</ref>
*[[Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)]] should be used with caution in patients with acute heart failure due to their effect on fluid and sodium retention.<ref name="pmid12656651">{{Cite pmid|12656651}}</ref>
*Patients with [[chronic heart failure]] are recommended to continue their previous guideline-directed medical therapy, including [[beta-blockers]], [[ACE inhibitors]] or [[Angiotensin II receptor blockers]], and [[mineralocorticoid receptor antagonists]]. <ref name="pmid31129923">{{Cite pmid|31129923}}</ref>
*Patients with chronic heart failure are recommended to continue their previous guideline-directed medical therapy, including [[beta-blockers]], [[ACEI]] or [[ARB]], and [[mineralocorticoid receptor antagonists]]. <ref name="pmid31129923">{{Cite pmid|31129923}}</ref>


==References==
==References==

Revision as of 21:55, 29 June 2020

For COVID-19 frequently asked inpatient questions, click here
For COVID-19 frequently asked outpatient questions, click here

WikiDoc Resources for COVID-19-associated heart failure

Articles

Most recent articles on COVID-19-associated heart failure

Most cited articles on COVID-19-associated heart failure

Review articles on COVID-19-associated heart failure

Articles on COVID-19-associated heart failure in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on COVID-19-associated heart failure

Images of COVID-19-associated heart failure

Photos of COVID-19-associated heart failure

Podcasts & MP3s on COVID-19-associated heart failure

Videos on COVID-19-associated heart failure

Evidence Based Medicine

Cochrane Collaboration on COVID-19-associated heart failure

Bandolier on COVID-19-associated heart failure

TRIP on COVID-19-associated heart failure

Clinical Trials

Ongoing Trials on COVID-19-associated heart failure at Clinical Trials.gov

Trial results on COVID-19-associated heart failure

Clinical Trials on COVID-19-associated heart failure at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on COVID-19-associated heart failure

NICE Guidance on COVID-19-associated heart failure

NHS PRODIGY Guidance

FDA on COVID-19-associated heart failure

CDC on COVID-19-associated heart failure

Books

Books on COVID-19-associated heart failure

News

COVID-19-associated heart failure in the news

Be alerted to news on COVID-19-associated heart failure

News trends on COVID-19-associated heart failure

Commentary

Blogs on COVID-19-associated heart failure

Definitions

Definitions of COVID-19-associated heart failure

Patient Resources / Community

Patient resources on COVID-19-associated heart failure

Discussion groups on COVID-19-associated heart failure

Patient Handouts on COVID-19-associated heart failure

Directions to Hospitals Treating COVID-19-associated heart failure

Risk calculators and risk factors for COVID-19-associated heart failure

Healthcare Provider Resources

Symptoms of COVID-19-associated heart failure

Causes & Risk Factors for COVID-19-associated heart failure

Diagnostic studies for COVID-19-associated heart failure

Treatment of COVID-19-associated heart failure

Continuing Medical Education (CME)

CME Programs on COVID-19-associated heart failure

International

COVID-19-associated heart failure en Espanol

COVID-19-associated heart failure en Francais

Business

COVID-19-associated heart failure in the Marketplace

Patents on COVID-19-associated heart failure

Experimental / Informatics

List of terms related to COVID-19-associated heart failure

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mitra Chitsazan, M.D.[2]Mandana Chitsazan, M.D. [3]

Synonyms and keywords: coronavirus disease-19, coronavirus disease 2019, SARS-CoV-2, COVID-19, 2019-nCoV, 2019 novel coronavirus, acute heart failure, de novo acute heart failure, chronic heart failure, acute decompensated heart failure, HFrEF, HFpEF, heart failure with reduced ejection fraction, heart failure with preserved ejection fraction

Overview

Historical perspective

Classification

  • Heart Failure in COVID-19 may be classified similarly to heart failure from other causes.
  • In general, HF can be classified based on:
    • The pathophysiology of heart failure:
      • systolic vs diastolic
      • left-sided vs right-sided
    • The duration of symptoms:
      • acute vs chronic
    • The underlying physiology based on left ventricular ejection fraction (LVEF):
      • Heart failure with reduced ejection fraction (HFrEF) vs heart failure with mid-range ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF),
    • The severity of heart failure (i.e., the New York Heart Association Class I-IV)
    • The stage of congestive heart failure (i.e., AHA Class A, B, C, D)
  • Acute heart failure has two forms:
    • Newly-arisen (“de novo”) acute heart failure
    • Acutely decompensated chronic heart failure (ADCHF)

Pathophysiology

  • Presumed pathophysiologic mechanisms for the development of new or decompensated heart failure in patients with COVID-19 include:[1] [2] [3] [4] [5]

Causes

  • Acute myocardial injury
  • Acute coronary syndromes
  • Myocarditis
  • Hypertensive crisis
  • Arrhythmias: Tachycardia or severe bradycardia
  • Stress-induced cardiomyopathy
  • Circulatory failure:
    • Acute pulmonary embolism
    • Pericardial tamponade
  • Iatrogenic


Differentiating ((COVID-19 associated heart failure)) from other Diseases

In patients with COVID-19 infection, acute heart failure should be differentiated from other diseases presenting with dyspnea and/or tachypnea. The differentials include the following:

  • Pneumonia
  • ARDS
  • Myocarditis/pericarditis
  • Acute pulmonary embolism


Epidemiology and Demographics

  • In one study, acute heart failure was seen in 4.1% of patients with acute cardiac injury.
  • In a retrospective study on study 191 COVID-19 patients in Wuhan, China, the incidence of heart failure was 23% (52% in non-survivors vs 12% in survivors).

Risk Factors

Screening

  • There is insufficient evidence to recommend routine screening for heart failure in COVID-19 patients.
  • Routine measurement of natriuretic peptides and/or cardiac troponins have not been recommended in the absence of a high index of suspicion for HF on the clinical grounds.

Natural History, Complications, and Prognosis

  • COVID-19 patients with chronic heart failure are more likely to develop severe forms of the disease.
  • COVID-19 patients who develop acute heart failure (either de novo AHF or ADHF) have worse outcomes.
  • Acute heart failure in COVID-19 may progress to cardiogenic shock.

Diagnosis

Diagnostic Study of Choice

History and Symptoms

  • The most common symptoms of acute heart failure in COVID-19 patients are:
    • New or worsening dyspnea: may overlap with dyspnea caused by concomitant respiratory involvement and ARDS due to COVID-19
    • Peripheral edema
    • Confusion and altered mentation
    • Orthopnea
    • Palpitations
    • Paroxysmal nocturnal dyspnea
    • Cool extremities
    • Cyanosis
    • Dizziness
    • Syncope
    • Fatigue
    • Hemoptysis

Physical Examination

  • Physical examination of patients with acute heart failure is usually remarkable for:
    • Crackles on auscultation
    • Distended jugular veins
    • Lower extremity edema

Laboratory Findings

  • Cardiac Troponins:
    • Elevated cardiac troponin levels suggest the presence of myocardial cell injury or death.
    • Cardiac troponin levels may increase in patients with chronic or acute decompensated HF.[6]
  • Natriuretic Peptides:
    • Natriuretic peptides (BNP/NT-proBNP) are released from the heart in response to increased myocardial stress and are quantitative markers of increased intracardiac filling pressure.[7]
    • Elevated BNP and NT-proBNP are of both diagnostic and prognostic significance in patients with heart failure.
    • Increased BNP or NT-proBNP levels have been demonstrated in COVID-19 patients.
    • Increased NT-proBNP level was associated with worse clinical outcomes in patients with severe COVID-19.[8] [9]
    • However, increased natriuretic peptide levels are frequently seen among patients with severe inflammatory or respiratory diseases.[10] [11] [12] [13] [14]
    • Therefore, routine measurement of BNP/NT-proBNP has not been recommended in COVID-19 patients, unless there is a high suspicion of HF based on clinical grounds.

Electrocardiogram

X-ray

  • An x-ray may be helpful in the diagnosis of heart failure. Findings on an x-ray suggestive of heart failure include:
    • Cardiomegaly
    • Pulmonary congestion
    • Increased pulmonary vascular markings.
  • However, signs of pulmonary edema may be obscured by underlying respiratory involvement and ARDS due to COVID-19.

Echocardiography or Ultrasound

  • A complete standard transthoracicechocardiography (TTE) has not been recommended in COVID-19 patients considering the limited personal protective equipment (PPE) and the risk of exposure of additional health care personnel.[15]
  • To deal with limited resources (both personal protective equipment and personnel) and reducing the exposure time of personnel, a focused TTE to find gross abnormalities in cardiac structure/function seems satisfactory.
  • In addition, bedside options, which may be performed by the trained personnel who might already be in the room with these patients, might also be considered. These include:
  • Cardiac ultrasound can help in assessing the following parameters:
    • Left ventricular systolic function (ejection fraction) to distinguish systolic dysfunction with a reduced ejection fraction (<40%) from diastolic dysfunction with a preserved ejection fraction.
    • Left ventricular diastolic function
    • Left ventricular structural abnormalities, including LV size and LV wall thickness
    • Left atrial size
    • Right ventricular size and function
    • Detection and quantification of valvular abnormalities
    • Measurement of systolic pulmonary artery pressure
    • Detection and quantification of pericardial effusion
    • Detection of regional wall motion abnormalities/reduced strain that would suggest underlying ischemia.

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

References

  1. ↑ Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D; et al. (2020). "Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19)". JAMA Cardiol. doi:10.1001/jamacardio.2020.1096. PMID 32219357 Check |pmid= value (help).
  2. ↑ PMID 32360242 (PMID 32360242)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  3. ↑ PMID 32186331 (PMID 32186331)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  4. ↑ PMID 30625066 (PMID 30625066)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  5. ↑ PMID 32140732 (PMID 32140732)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  6. ↑ PMID 20863950 (PMID 20863950)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  7. ↑ PMID 28062628 (PMID 28062628)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  8. ↑ PMID 32293449 (PMID 32293449)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  9. ↑ PMID 32232979 (PMID 32232979)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  10. ↑ PMID 18298480 (PMID 18298480)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  11. ↑ PMID 16442916 (PMID 16442916)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  12. ↑ PMID 28322314 (PMID 28322314)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  13. ↑ PMID 23837838 (PMID 23837838)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  14. ↑ PMID 21478812 (PMID 21478812)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  15. ↑ PMID 32391912 (PMID 32391912)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  16. ↑ PMID 24251454 (PMID 24251454)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  17. ↑ PMID 12656651 (PMID 12656651)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  18. ↑ PMID 31129923 (PMID 31129923)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=COVID-19-associated_heart_failure&oldid=1619356"